Enzalutamide: A Review of Its Use in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

@article{Keating2015EnzalutamideAR,
  title={Enzalutamide: A Review of Its Use in Chemotherapy-Na{\"i}ve Metastatic Castration-Resistant Prostate Cancer},
  author={Gillian M. Keating},
  journal={Drugs \& Aging},
  year={2015},
  volume={32},
  pages={243-249}
}
Enzalutamide (Xtandi®) is an androgen receptor inhibitor that blocks several steps in the androgen receptor signalling pathway. This article reviews the clinical efficacy and tolerability of oral enzalutamide in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC), as well as summarizing its pharmacological properties. In the randomized, double-blind, multinational PREVAIL trial, enzalutamide significantly improved both radiographic progression-free survival and… Expand
Enzalutamide: A Review in Castration-Resistant Prostate Cancer
TLDR
Ezalutamide is an emerging option for the treatment of men with nonmetastatic CRPC who are at high-risk for developing metastatic disease, and remains an important first-line option in chemotherapy-naive or -experienced patients with metastaticCRPC. Expand
Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference☆
TLDR
Significant advances in the understanding of the androgen pathway role over the last decade have led to the development of alternative novel hormonal agents such as abiraterone and enzalutamide to treat advanced castration-resistant prostate cancer. Expand
Androgen Receptor as a Potential Target for Treatment of Breast Cancer
  • Y. Wu, J. Vadgama
  • Medicine
  • International journal of cancer research and molecular mechanisms
  • 2017
TLDR
The role of AR in different subtypes of breast cancers is reviewed and its mechanisms are elucidated to better understand its mechanisms. Expand
Structural elucidation of the impurities in Enzalutamide bulk drug and the development, validation of corresponding HPLC method.
TLDR
An efficient chromatographic method was developed and demonstrated to be applicable in routine quality control and stability evaluation of Enzalutamide and was validated with respect to specificity, precision, accuracy, and sensitivity. Expand
Quantitative Study of Impurities in Enzalutamide and Identification, Isolation, Characterization of Its Four Degradation Products Using HPLC, Semi-preparative LC, LC/ESI–MS and NMR Analyses
Enzalutamide was recently approved for the treatment of castration-resistant prostate cancer. In this study, the related substances in enzalutamide bulk substance were analyzed qualitatively andExpand

References

SHOWING 1-10 OF 49 REFERENCES
Enzalutamide: A Review of Its Use in Metastatic, Castration-Resistant Prostate Cancer
TLDR
In a randomized, double-blind, placebo-controlled, multinational, phase III trial in patients with mCRPC progressing after docetaxel therapy, enzalutamide significantly prolonged overall survival, delayed prostate specific antigen progression and prolonged radiographic progression-free survival and time to the first skeletal event. Expand
Enzalutamide in metastatic prostate cancer before chemotherapy.
TLDR
Enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer. Expand
Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
TLDR
Although a large majority of patients responded favorably to enzalutamide in the prechemotherapy setting, a small but significant proportion of patients demonstrated no meaningful benefit to this agent, highlighting an important concept in the understanding of this disease: inherent and acquired resistance to AR-targeting therapies. Expand
Increased survival with enzalutamide in prostate cancer after chemotherapy.
TLDR
Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy, and was shown with respect to all secondary end points. Expand
Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
TLDR
This is a single-center, retrospective analysis of 23 patients with mCRPC who received enzalutamide after progression on abiraterone, finding paucity of information regarding sequential use of enzalUTamide after abIRaterone. Expand
767PRESPONSE RATES AND OUTCOMES WITH ENZALUTAMIDE FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER AND VISCERAL DISEASE IN THE PREVAIL TRIAL.
  • C. Higano, J. Alumkal, +10 authors T. Beer
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
TLDR
The results support androgen receptor signaling as an important target in prostate cancer with visceral metastases in men with chemotherapy-naive men with asymptomatic or mildly symptomatic mCRPC. Expand
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
TLDR
Although cross-resistance between abiraterone and enzalutamide was a common phenomenon, it was not inevitable, and a small but significant number of patients showed significant benefit from sequential treatment. Expand
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
BACKGROUND Abiraterone acetate (AA) has demonstrated improved outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). However, data are lacking on the effect of AA on subsequentExpand
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
TLDR
Previous abiraterone therapy is associated with a less marked fall in PSA following enzalutamide therapy in post-chemotherapy mCRPC patients compared with reported results in randomized trials. Expand
Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.
TLDR
Primary outcomes were PSA response rate (confirmed decline ≥ 50%) and time to treatment failure (TTF, defined as the time from treatment initiation to treatment discontinuation for any reason, including disease progression, treatment toxicity, patient preference, or death.). Expand
...
1
2
3
4
5
...